Health
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment...
About this update from Oculis Holding Ag
[{"type":"image","alt":"Oculis Holding AG","displaySize":"","headline":null,"caption":"Oculis Holding AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/8ad7f9a35e702253b405c1e1f0eb1cf9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9Tx1uuuzsErM0lxb4iyrCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8ad7f9a35e702253b405c1e1f0eb1cf9","width":300,"height":75}},"lazy":false},{"type":"text","content":"ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) --","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":121,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S.","length":166,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":166,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroid alone at month 3 in the ACUITY trial","length":147,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":147,"olType":false},{"type":"text","content":"Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for treatment of optic neuritis (ON).","length":404,"tagName":"p"},{"type":"text","content":"Privosegtor, a novel peptoid small molecule designed to cross both the blood–brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuropathies. These serious conditions carry a significant unmet need, because they can lead to permanent vision loss from nerve cell damage or death. There are no neuroprotective treatments currently ava...